Srivatsan Raghavan

4.4k total citations
29 papers, 1.2k citations indexed

About

Srivatsan Raghavan is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Srivatsan Raghavan has authored 29 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Oncology and 9 papers in Cell Biology. Recurrent topics in Srivatsan Raghavan's work include Cellular Mechanics and Interactions (9 papers), Pancreatic and Hepatic Oncology Research (8 papers) and 3D Printing in Biomedical Research (8 papers). Srivatsan Raghavan is often cited by papers focused on Cellular Mechanics and Interactions (9 papers), Pancreatic and Hepatic Oncology Research (8 papers) and 3D Printing in Biomedical Research (8 papers). Srivatsan Raghavan collaborates with scholars based in United States, United Kingdom and Switzerland. Srivatsan Raghavan's co-authors include Christopher S. Chen, Celeste M. Nelson, John L. Tan, Wendy F. Liu, Ravi A. Desai, Lin Gao, Wendy Liu, Jan D. Baranski, Emerson A. Lim and Lewis H. Romer and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Srivatsan Raghavan

25 papers receiving 1.2k citations

Peers

Countries citing papers authored by Srivatsan Raghavan

Since Specialization

Citations

This map shows the geographic impact of Srivatsan Raghavan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srivatsan Raghavan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srivatsan Raghavan more than expected).

Fields of papers citing papers by Srivatsan Raghavan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srivatsan Raghavan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srivatsan Raghavan. The network helps show where Srivatsan Raghavan may publish in the future.

Co-authorship network of co-authors of Srivatsan Raghavan

This figure shows the co-authorship network connecting the top 25 collaborators of Srivatsan Raghavan. A scholar is included among the top collaborators of Srivatsan Raghavan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srivatsan Raghavan. Srivatsan Raghavan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity 2025 ·Nature Communications ·Stephanie Dobersch, Naomi Yamamoto, (unknown), (unknown), Thomas Robertson, (unknown), Annie N. Samraj, (unknown), (unknown), (unknown), Amy X. Zhang, Gun Ho Jang, (unknown), Guillermo Barreto, Srivatsan Raghavan, Goutham Narla, Faiyaz Notta, Robert N. Eisenman, Andrew C. Hsieh, Sita Kugel	0
2	Artificial variables help to avoid over-clustering in single-cell RNA sequencing 2025 ·The American Journal of Human Genetics ·Alan DenAdel, (unknown), Andrew W. Navia, Alex K. Shalek, Srivatsan Raghavan, Peter Winter, Ava P. Amini, Lorin Crawford	1
3	798 TGFβ blockade in pancreatic cancer enhances sensitivity to combination chemotherapy 2023 ·SHILAP Revista de lepidopterología ·Qiang Li, Megan T. Hoffman, Lestat R. Ali, (unknown), (unknown), Patrick J. Lenehan, (unknown), Jennifer Wang, (unknown), Victoire Cardot‐Ruffino, Giselle A. Uribe, Annan Yang, Michael Dougan, Andrew J. Aguirre, Srivatsan Raghavan, Marc R. Pelletier, Viviana Cremasco, Stephanie K. Dougan	0
4	Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy 2023 ·Gastroenterology ·Qiang Li, Megan T. Hoffman, Lestat R. Ali, (unknown), (unknown), (unknown), Patrick J. Lenehan, (unknown), (unknown), Victoire Cardot‐Ruffino, Giselle A. Uribe, Annan Yang, Michael Dougan, Andrew J. Aguirre, Srivatsan Raghavan, Marc R. Pelletier, Viviana Cremasco, Stephanie K. Dougan	43
5	USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities 2023 ·Cell Reports Medicine ·Naiara Perurena, Rebecca Lock, (unknown), Srivatsan Raghavan, (unknown), Raymond W.S. Ng, (unknown), (unknown), Abigail L. Miller, Ewa Sicińska, James M. Cleary, Douglas A. Rubinson, Brian M. Wolpin, Nathanael S. Gray, Sandro Santagata, William C. Hahn, Jennifer P. Morton, Owen J. Sansom, Andrew J. Aguirre, Karen Cichowski	5
6	RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition 2022 ·Nature Communications ·Lishan Fang, (unknown), (unknown), (unknown), Xiaozhe Xiong, Carino Gurjao, Maximilien Grandclaudon, Srivatsan Raghavan, Steven M. Corsello, Steven A. Carr, Namrata D. Udeshi, James Berstler, Ewa Sicińska, Kimmie Ng, Marios Giannakis	32
7	Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma 2022 ·npj Precision Oncology ·James M. Cleary, (unknown), Antoine Daina, Srivatsan Raghavan, (unknown), Brandon M. Huffman, Harshabad Singh, Patrick Y. Wen, Nabeel Bardeesy, Vincent Zoete, Brian M. Wolpin, Julie-Aurore Losman	52
8	Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma. 2020 ·Journal of Clinical Oncology ·James M. Cleary, Srivatsan Raghavan, Yvonne Y. Li, Liam F. Spurr, Qibiao Wu, Lei Shi, Lauren K. Brais, (unknown), Lipika Goyal, Anuj Patel, Atul B. Shinagare, Thomas E. Clancy, Geoffrey I. Shapiro, Ethan Cerami, William R. Sellers, William C. Hahn, Andrew D. Cherniack, Nabeel Bardeesy, Matthew Meyerson, Brian M. Wolpin	1
9	Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer. 2020 ·Journal of Clinical Oncology ·Kimberly Perez, Colin D. Weekes, James M. Cleary, Thomas A. Abrams, Lawrence S. Blaszkowsky, Peter C. Enzinger, Marios Giannakis, Lipika Goyal, Jeffrey A. Meyerhardt, Douglas A. Rubinson, Matthew B. Yurgelun, (unknown), Srivatsan Raghavan, Basil Bakir, Koushik K. Das, Jason R. Pitarresi, Andrew J. Aguirre, Michael N. Needle, Anil K. Rustgi, Brian M. Wolpin	4
10	Non-viral delivery of CRISPR/Cas9 complex using CRISPR-GPS nanocomplexes 2019 ·Nanoscale ·Piyush Jain, Justin H. Lo, Santosh R. Rananaware, (unknown), Apekshya Panda, (unknown), Srivatsan Raghavan, Heather E. Fleming, Sangeeta N. Bhatia	35
11	iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer 2018 ·Molecular Cancer Therapeutics ·Justin H. Lo, Liangliang Hao, Mandar D. Muzumdar, Srivatsan Raghavan, Ester J. Kwon, Emilia M. Pulver, (unknown), Andrew J. Aguirre, Brian M. Wolpin, Charles S. Fuchs, William C. Hahn, Tyler Jacks, Sangeeta N. Bhatia	65
12	Metastatic Pancreatic Neuroendocrine Tumor with Ectopic Adrenocorticotropic Hormone Production 2015 ·Baylor University Medical Center Proceedings ·Muthiah Vaduganathan, (unknown), Darcy A. Kerr, Kelly Lauter, Arun Padmanabhan, Srivatsan Raghavan, J. Carl Pallais, Andrew Z. Fenves	4
13	Manipulation of 3D Cluster Size and Geometry by Release from 2D Micropatterns 2012 ·Cellular and Molecular Bioengineering ·Jennifer L. Leight, Wendy F. Liu, Ritika Chaturvedi, Sophia Chen, Michael T. Yang, Srivatsan Raghavan, Christopher S. Chen	12
14	Decreased cell adhesion promotes angiogenesis in a Pyk2-dependent manner 2011 ·Experimental Cell Research ·Colette J. Shen, Srivatsan Raghavan, Zhe Xu, Jan D. Baranski, Xiang Yu, Michele A. Wozniak, Jordan S. Miller, (unknown), Leonard Buckbinder, Christopher S. Chen	31
15	Geometrically Controlled Endothelial Tubulogenesis in Micropatterned Gels 2010 ·Tissue Engineering Part A ·Srivatsan Raghavan, Celeste M. Nelson, Jan D. Baranski, Emerson A. Lim, Christopher S. Chen	133
16	Decoupling diffusional from dimensional control of signaling in 3D culture reveals a role for myosin in tubulogenesis 2010 ·Development ·Srivatsan Raghavan, Colette J. Shen, Ravi A. Desai, Nathan J. Sniadecki, Celeste M. Nelson, Christopher S. Chen	1
17	Decoupling diffusional from dimensional control of signaling in 3D culture reveals a role for myosin in tubulogenesis 2010 ·Journal of Cell Science ·Srivatsan Raghavan, Colette J. Shen, Ravi A. Desai, Nathan J. Sniadecki, Celeste M. Nelson, Christopher S. Chen	43
18	An inhibitory role for FAK in regulating proliferation: a link between limited adhesion and RhoA-ROCK signaling 2006 ·The Journal of Cell Biology ·Dana M. Pirone, Wendy F. Liu, Sami Alom Ruiz, Lin Gao, Srivatsan Raghavan, Christopher A. Lemmon, Lewis H. Romer, Christopher S. Chen	148
19	Simple Approach to Micropattern Cells on Common Culture Substrates by Tuning Substrate Wettability 2004 ·Tissue Engineering ·John L. Tan, Wendy Liu, Celeste M. Nelson, Srivatsan Raghavan, Christopher S. Chen	184
20	Fractional Precipitation of Star Poly(ethylene oxide) 1996 ·Macromolecules ·(unknown), Srivatsan Raghavan, Edward W. Merrill	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact